SCHEMBL3677820

SCHEMBL3677820

CCC(C)(O)CBr

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL4309093 0.87 LMNA (0.38)
SCHEMBL6293876 0.82
SCHEMBL23931 0.78
SCHEMBL10339069 0.75
Ammonia Solution, Strong SCHEMBL441052 0.74
SCHEMBL1614263 0.74
SCHEMBL10821853 0.74
Hydrochloric Acid SCHEMBL28719957 0.74
SCHEMBL12479851 0.74
Tert-Butanol SCHEMBL11220086 0.74 TSHR (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313968-A2 SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2024-02-07 EP disclosed
CN-109153653-A New compound, Photocurable composition, its solidfied material, printing ink and the printed article for having used the printing ink DIC株式会社 2019-01-04 CN disclosed
EP-2150258-A2 IMPROVED METHODS OF USING PHOSPHOANTIGENS TOGETHER WITH INTERLEUKIN-2 FOR THE TREATMENT OF CANCER Innate Pharma S.A. (FR) 2010-02-10 EP disclosed
WO-2008146167-A2 IMPROVED METHODS OF USING PHOSPHOANTIGENS TOGETHER WITH INTERLEUKIN-2 FOR THE TREATMENT OF CANCER INNATE PHARMA S.A. (FR) 2008-12-04 WO disclosed